TGFB1 and neoplasm: Finally, we propose a therapeutic alternative for TNBC patients, whose overexpression of NDRG1 is associated with poorer survival and TGFβ1 status, by the combination of TGFβ and GSK3β inhibitors to potentially preventing tumor progression, recurrence, and chemoresistance.